» Articles » PMID: 26362292

Considerations About Antimicrobial Stewardship in Settings with Epidemic Extended-Spectrum β-Lactamase-Producing or Carbapenem-Resistant Enterobacteriaceae

Overview
Journal Infect Dis Ther
Date 2015 Sep 13
PMID 26362292
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Infections caused by gram-negative bacteria (GNB) resistant to multiple classes of antibiotics are increasing in many hospitals. Extended-spectrum β-lactamase (ESBL)-producing and carbapenem-resistant Enterobacteriaceae in particular are now endemic in many parts of the world and represent a serious public health threat. In this era, antimicrobial stewardship programs are essential as targeted and responsible use of antibiotics improves patient outcomes and hopefully limits the selective pressure that drives the further emergence of resistance. However, some stewardship strategies aimed at promoting carbapenem-sparing regimens remain controversial and are difficult to implement when resistance rates to non-carbapenem antibiotics are increasing. Coordinated efforts between stewardship programs and infection control are essential for reversing conditions that favor the emergence and dissemination of multidrug-resistant GNB within the hospital and identifying extra-institutional "feeder reservoirs" of resistant strains such as long-term care facilities, where colonization is common despite limited numbers of serious infections. In settings where ESBL resistance is endemic, the cost-effectiveness of expanded infection control efforts and antimicrobial stewardship is still unknown. Once a patient has been colonized, selective oral or digestive decontamination may be considered, but evidence supporting its effectiveness is limited in patients who are already colonized or in centers with high rates of resistance. Moreover, temporary success at decolonization may be associated with a higher risk of relapse with strains that are resistant to the decolonizing antibiotics.

Citing Articles

The Effect of Antibiotics on the Eradication of Multidrug-Resistant Organisms in Intestinal Carriers-A Systematic Review with Meta-Analysis.

Knudsen M, Rubin I, Petersen A Antibiotics (Basel). 2024; 13(8).

PMID: 39200047 PMC: 11350669. DOI: 10.3390/antibiotics13080747.


The role of community pharmacists and their perception towards antimicrobial stewardship in Baghdad, Iraq.

Alkadhimi A, Dawood O, Khan A Health Care Sci. 2024; 3(2):114-123.

PMID: 38939617 PMC: 11080847. DOI: 10.1002/hcs2.92.


Impact of COVID-19 on antimicrobial stewardship activities in Italy: a region-wide assessment.

Vicentini C, Corcione S, Moro G, Mara A, De Rosa F, Zotti C Antimicrob Resist Infect Control. 2024; 13(1):48.

PMID: 38725026 PMC: 11084085. DOI: 10.1186/s13756-024-01407-3.


The molecular detection of carbapenem markers with a two-levels amplification screening protocol: epidemiological and resistome insights.

Calvo M, Migliorisi G, Maugeri G, Bongiorno D, Bonomo C, Nicitra E Front Microbiol. 2024; 15:1346442.

PMID: 38585692 PMC: 10996853. DOI: 10.3389/fmicb.2024.1346442.


Extended-Spectrum β-Lactamase and Carbapenemase-Producing Gram-Negative Bacteria and Associated Factors Among Patients Suspected of Community and Hospital-Acquired Urinary Tract Infections at Ayder Comprehensive Specialized Hospital, Tigrai,....

Gebremedhin M, Weldu Y, Kahsay A, Teame G, Adane K Infect Drug Resist. 2023; 16:4025-4037.

PMID: 37383605 PMC: 10295491. DOI: 10.2147/IDR.S412350.


References
1.
Tan K, Ellis B, Lee R, Stamper P, Zhang S, Carroll K . Prospective evaluation of a matrix-assisted laser desorption ionization-time of flight mass spectrometry system in a hospital clinical microbiology laboratory for identification of bacteria and yeasts: a bench-by-bench study for assessing the impact.... J Clin Microbiol. 2012; 50(10):3301-8. PMC: 3457442. DOI: 10.1128/JCM.01405-12. View

2.
Taylor M, Oppenheim B . Selective decontamination of the gastrointestinal tract as an infection control measure. J Hosp Infect. 1991; 17(4):271-8. DOI: 10.1016/0195-6701(91)90271-9. View

3.
Paterson D, Ko W, von Gottberg A, Mohapatra S, Casellas J, Goossens H . Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis. 2004; 39(1):31-7. DOI: 10.1086/420816. View

4.
Lew K, Ng T, Tan M, Tan S, Lew E, Ling L . Safety and clinical outcomes of carbapenem de-escalation as part of an antimicrobial stewardship programme in an ESBL-endemic setting. J Antimicrob Chemother. 2014; 70(4):1219-25. DOI: 10.1093/jac/dku479. View

5.
Harris P, Tambyah P, Paterson D . β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?. Lancet Infect Dis. 2015; 15(4):475-85. DOI: 10.1016/S1473-3099(14)70950-8. View